AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US

GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde

The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde

FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access

Thermo Fisher Scientific to invest $2 billion to expand US operation

Investment demonstrates confidence in America’s commitment to science and innovation

Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA

Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities

J&J to break ground on new biologics facility in North Carolina

New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases

Croda opens advanced lipids manufacturing facility in Pennsylvania

This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million

Bionova opens Fremont process development and pilot plant